4069 results about "Cvd risk" patented technology

The invention relates to a method which utilizes blood glucose (“BG”) sampling, insulin infusion/injection records, heart rate (“HR”) information and heart rate varability (“HRV”) information to estimate BG in the near future and to estimate of the risk of the onset of hypoglycemia. The invention also relates to an apparatus for predicting BG levels and for assessing the risk of the onset of hypoglycemia in the near future. The invention is based on two predetermined bio-mathematical routines: a network model of BG fluctuations and a BG profile for assessment of the risk of hypoglycemia.

A method and apparatus for the transcutaneous monitoring of blood gases generally comprises a blood gas data acquisition device, a vacuum source and a blood gas transducer unit. The blood gas transducer unit is adapted for application to a patient's skin and administration of a local vacuum at the area of patient application. It further comprises an electrochemical blood gas transducer, well known to those of ordinary skill in the art, which is disposed entirely within the local vacuum at the area of patient application. The vacuum source is placed in fluid communication with the blood gas transducer unit, through a hydrophobic membrane filter for safety purposes, in order to induce a condition of hyperperfusion in the locality of the electrochemical blood gas transducer. Under the control of a microcontroller, or equivalent means, the blood gas acquisition device is then utilized to capture a measure of skin surface oxygen or carbon dioxide pressure. The microcontroller can then utilize this measure to arrive at an estimate of arterial partial pressure of oxygen or carbon dioxide, accordingly. Because vacuum induced perfusion produces the requisite condition of hyperperfusion without local heating and, therefore, without acceleration of the local metabolic function, the present invention results in more accurate than previously available estimates of partial pressure blood gas pressures and does so while eliminating a significant risk for injury to the patient.

Systems and methods are described for scoring consumers' credit risk by determining consumers' income risk and future ability to pay. Methods are provided for measuring consumers' income risk by analyzing consumers' income loss risk, income reduction risk, probability of continuance of income, and economy's impact on consumers' income. In one embodiment, a method is provided to evaluate an individual's creditworthiness using income risk based credit score thereby providing creditors, lenders, marketers, and companies with deeper, new insights into consumer's credit risk and repayment potential. By predicting consumers' income risk and the associated creditworthiness the present invention increases the accuracy and reliability of consumers' credit risk assessments, results in more predictive and precise consumer credit scoring, and offers a new method of rendering a forward-looking appraisal of an individual's ability to repay a debt or the ability to pay for products and services.

The present invention is directed to drug dosage forms that release an agent that raises the pH of a patient's gastrointestinal tract, followed by a non-steroidal anti-inflammatory drug. The dosage form is designed so that the NSAID is not released until the intragastric pH has been raised to a safe level. The invention also encompasses methods of treating patients by administering this coordinated release, gastroprotective, antiarthritic/analgesic combination unit dosage form to achieve pain and symptom relief with a reduced risk of developing gastrointestinal damage such as ulcers, erosions and hemorrhages.

A method is provided, including identifying that a subject is at risk of suffering from atrial fibrillation (AF). Responsively to the identifying, a risk of an occurrence of an episode of the AF is reduced by coupling an electrode device to a site of a subject containing parasympathetic nervous tissue; driving, by a control unit, the electrode device to apply an electrical current to the site not responsively to any physiological parameters sensed by any device directly or indirectly coupled to the control unit; and configuring the current to stimulate autonomic nervous tissue in the site. Other embodiments are also described.

Sympathetic nerves run through the adventitia surrounding renal arteries and are critical in the modulation of systemic hypertension. Hyperactivity of these nerves can cause renal hypertension, a disease prevalent in 30-40% of the adult population. Hypertension can be treated with neuromodulating agents (such as angiotensin converting enzyme inhibitors, angiotensin II inhibitors, or aldosterone receptor blockers), but requires adherence to strict medication regimens and often does not reach target blood pressure threshold to reduce risk of major cardiovascular events. A minimally invasive solution is presented here to reduce the activity of the sympathetic nerves surrounding the renal artery by locally delivering neurotoxic or nerve-blocking agents into the adventitia. Extended elution of these agents may also be accomplished in order to tailor the therapy to the patient.

A method and apparatus for providing real-time support in interpreting a patient's ECG in order to assess the probability of perioperative cardiovascular risk associated with performing a non-cardiac surgery. The apparatus includes an acquisition unit for acquiring an ECG and a processor for determining whether the ECG has diagnostic statements of risk. From the diagnostic statements of risk, the processor determines the probability of cardiovascular risk associated with the non-cardiac surgery. The probability of cardiovascular risk is displayed on display in the form of an indicator of either major, intermediate, or minor cardiovascular risk.

The method includes acquiring a patient's ECG, determining whether the ECG exhibits diagnostic statements of cardiovascular risk, and determining the probability of cardiovascular risk based on the diagnostic statements, and displaying the determined probability of cardiovascular risk.

Methods and devices are disclosed for detecting vulnerable atherosclerotic plaque, or plaque at risk of reducing blood flow in a vessel, by identifying a region of elevated temperature along a living vessel wall. The disclosure that human atherosclerotic plaque with measurable temperature heterogeneity has the morphological characteristics of plaque that is likely to ulcerate provides a new and sensitive technique for detecting and treating these dangerous plaques before myocardial infarction and its consequences occur. The disclosed methods are advantageous over conventional plaque detection techniques because they are capable of differentiating between those plaques that are at great risk of rupture, fissure, or ulceration, and consequent thrombosis and occlusion of the artery, and those that are not presently at risk. Infrared heat-sensing catheters useful for identifying potentially fatal arterial plaques in patients with disease of the coronary or other arteries are also described. In some embodiments a coherent infrared fiber optic bundle is employed to radially and longitudinally explore a luminal wall to identify inflamed, heat-producing, atherosclerotic plaque. Certain other methods and devices are disclosed which are particularly suited for non-invasively identifying and then monitoring the progression or amelioration of an inflamed plaque in a patient, and for monitoring for onset of inflammation in an implanted arteriovenous graft. Also disclosed are thermocouple basket catheters and thermistor basket catheters which are also capable of detecting temperature heterogeneity along a vessel wall.

Systems, methods, apparatus and devices for performing improved gynecologic and urologic procedures using a flowable distension media are disclosed. The system and devices provide simplified use and reduced risk of adverse events. Patient benefit is achieved through improved outcomes, reduced pain, especially peri-procedural pain, and reduced recovery times. The various embodiments enable procedures to be performed outside the hospital setting, such as in a doctor's office or clinic.

A system and method for reducing the number of hypoglycemic alarms presented to a user is presented. The system and methods include use of model based state estimation and variable-delayed threshold values to balance the risk of not presenting an alarm caused by an actual hypoglycemic state with the presentation of alarms caused by artifacts in the signals produced by a continuous glucose monitor.

The present invention relates to methods, kits, combinations, and compositions for treating, preventing or reducing the risk of developing a testosterone deficient disorder, or the symptoms associated with, or related to a testosterone deficient disorder in a subject in need thereof. The present invention also relates to a method of administering a steroid in the testosterone synthetic pathway to a subject in need thereof. In addition, the methods, kits, combinations and compositions may be used in conjunction with other pharmaceutical agents effective at treating, preventing, or reducing the risk of developing a testosterone deficient disorder. The present invention also can also be used in conjunction with a pharmacologically effective amount of an estrogenic hormone. Furthermore, the methods, kits, combinations and compositions can be used in conjunction with a pharmacologically effective amount of another steroid or pharmaceutical agent that increases serum testosterone levels in a mammal.

The invention comprises methods for diagnosing the risk of onset of type 1 diabetes and for preventing the onset of type 1 diabetes. The genetic background, metabolomes, antibodies and diversity of gut microbiota of an individual can be used for diagnosis.

Methods and/or systems for diagnosing, monitoring and/or treating persons at risk for falling and/or other pathological conditions. In an exemplary embodiment of the invention, people are diagnosed before they actually start falling. Optionally, the diagnosis includes trying out and identifying one or more fall triggers using virtual reality tools. Optionally or alternatively, treatment includes training the persons using situations and/or triggers which are determined to be relevant for that person.

A method of predicting bone or articular disease in a subject includes determining one or more micro-structural parameters, one or more macroanatomical parameters or biomechanical parameters of a joint in the subject and combining at least two of the parameters to predict the risk of bone or articular disease.

Absorbable polyester fibers, braids, and surgical meshes with prolonged strength retention have been developed. These devices are preferably derived from biocompatible copolymers or homopolymers of 4-hydroxybutyrate. These devices provide a wider range of in vivo strength retention properties than are currently available, and could offer additional benefits such as anti-adhesion properties, reduced risks of infection or other post-operative problems resulting from absorption and eventual elimination of the device, and competitive cost. The devices may also be particularly suitable for use in pediatric populations where their absorption should not hinder growth, and provide in all patient populations wound healing with long-term mechanical stability. The devices may additionally be combined with autologous, allogenic and/or xenogenic tissues to provide implants with improved mechanical, biological and handling properties.

In order to avoid a sudden cardiac death by a fatal arrhythmia, various living body information for generating a signal which shows a level of an autonomic tone is detected by a sensor or a VT/VF risk event is detected so as to control the stimulation of the vagus nerve or the nerve stimulation waveform. For this purpose, the parameter of the nerve stimulation signal is controlled according to a detection of the living body information represented by a QT interval which is measured by intracardiac information of the heart or a detection of a VT/VF risk event represented by a ventricular premature contraction which is picked up from spontaneous cardiac events.

Novel chimeric fusion proteins comprising immunodominant epitopes of GAD and insulin are provided. Also provided are immunomodulatory methods for the use of such proteins for both the prevention and treatment of Type 1 diabetes mellitus. The chimeric fusion proteins of the invention are useful in predicting risk of onset of Type 1 diabetes, determining prognosis of Type 1 diabetes patients early in disease progression, and in evaluating patients for suitability as recipients of transplants of pancreatic cells or tissues. The administration of the proteins of the invention in accordance with the immunomodulatory methods of the invention results in beneficial effects on disease development and severity in patients suffering from or predicted to be at risk of developing Type 1 diabetes, as well as on the outcome of transplants of pancreatic cells or tissues in Type 1 diabetes patients.

The present invention restores the normal low-dose flushing of the lower airways with air from the upper airways, containing nitric oxide (NO) and possible other biologically active agents by aspiration of air from the upper airways and introducing said air in the inspiratory airflow of a ventilator. The inventive apparatus and method is free from the risks associated with traditional administration of exogenous NO.